News for Amgen Inc. (AMGN.MX)

Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to

STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) are approved by FDA for all indications of PROLIA® (denosumab) and XGEVA® (denosumab) respectively[1],[2] STOBOCLO and OSENVELT, among the first wave of biosimilars referencing PROLIA and XGEVA respectively, are commercially available in the U.S. Celltrion further expands its portfolio, delivering cost-effective and high-quality biologic medicines to wider range of patients in the U.S. JERSEY CITY, N.J., July 8, 2025 /PRNewswire/ -- Celltrion USA today announced that STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo), biosimilars referencing PROLIA® (denosumab) and XGEVA® (denosumab) respectively, are commercially available in the United States.

Amgen Inc. (NASDAQ:AMGN) is one of the 10 Best Dip Stocks to Buy According to Billionaires. On June 30, Amgen Inc. (NASDAQ:AMGN) announced positive topline results for an important phase 3 study of Bemarituzumab for certain stomach cancers. The company announced that the Phase 3 FORTITUDE-101 trial met its primary endpoint. The Bemarituzumab plus chemotherapy significantly improved […]

Wall Street optimistic for July 4 weekend, sees opportunities in Freeport-McMoRan, Honeywell, Caterpillar, and Amgen. Analysts raise targets.

Amgen Inc. (NASDAQ:AMGN) is one of the 10 Best Value Stocks to Buy According to Billionaires. On June 23, the company announced full results from Part 1 of the Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133), which is a long-acting, peptide-antibody conjugate subcutaneously administered monthly or less frequently. In the Phase 2 study, […]

Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Amgen Inc. (NASDAQ:AMGN) is one of the 11 stocks Jim Cramer put under the microscope recently. Cramer highlighted Wall Street’s reaction to the company’s latest data announcement regarding MariTide, and said: “Unlike Mounjaro or Ozempic, which needed to be injected once a week, Amgen’s MariTide is one shot per month. I prefer monthly over weekly […]

Microsoft is struggling to sell its Copilot AI assistant to corporations because many of their employees want ChatGPT.

Microsoft is struggling to sell its Copilot AI assistant to corporations because many of their employees want ChatGPT.

Amgen Inc. (NASDAQ:AMGN) Special Call (IR Call) Conference June 23, 2025 5:30 PM ETCompany ParticipantsJustin Claeys - Vice President of Investor Relations...

Amgen's new treatment, MariTide, shows promising weight loss results. Despite positive trial outcomes, AMGN shares saw a 6% dip. Analysts predict a potenti

Amgen (AMGN) shares dropped by $14.58, or 5%, reaching $274.75 in the afternoon trading session. This decline followed the company's announcement of detailed re

A heated debate over the U.S. healthcare system erupted on X, pitting billionaire entrepreneur Mark Cuban against Sen. Elizabeth Warren (D-Mass) over the root causes of soaring drug prices. What Happened: The clash, unfolding as of Friday, has ...

Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.

Amgen Inc. (AMGN) is poised to release significant findings from its MariTide obesity study. Analysts set a positive average price target, indicating po

Summary Amgen Inc (AMGN) announced on June 18, 2025, the full results from Part 1 of the Phase 2 study for MariTide, a peptide-antibody conjugate being investig

Amgen (AMGN) to present 52-week MariTide study results at ADA's 85th Scientific Sessions. Phase 2 data indicates significant weight loss without plateau

Amgen (AMGN) is set to reveal comprehensive results from the initial segment of its Phase 2 study on MariTide during the American Diabetes Association's 85th Sc